MEK Inhibitor News and Research

RSS

Researchers reveal how melanoma becomes resistant to promising new drug combo therapy

In a new study led by UCLA Jonsson Comprehensive Cancer Center member Dr. Roger Lo, researchers have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumor shrinkage.

16 Jan 2015

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve outcomes for many cancer patients, when compared to the adverse effects of standard chemotherapeutic drugs.

12 Jan 2015

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

CTI BioPharma Corp. today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays.

9 Dec 2014

New research suggests potential role for MEK inhibitors in type 2 diabetes

A research team led by Brigham and Women's Hospital and Dana-Farber Cancer Institute has uncovered surprising new findings that underscore the role of an important signaling pathway, already known to be critical in cancer, in the development of type 2 diabetes.

18 Nov 2014

Study reports anti-cancer activity in mice treated with experimental drug TAK-733

A University of Colorado Cancer Center study published online this week in the journal Molecular Cancer Therapeutics reports anti-cancer activity in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733, a small molecule inhibitor of MEK1/2.

12 Nov 2014

Researchers develop mouse model that reproduces most typical features of Noonan syndrome

Noonan syndrome is a rare disease that is characterised by a set of pathologies, including heart, facial and skeletal alterations, pulmonary stenosis, short stature, and a greater incidence of haematological problems (mainly juvenile myeloid leukaemia, or childhood leukaemia).

6 Nov 2014

Cancer Network presents exclusive coverage of ESMO 2014 Congress

UBM Medica US announces that Cancer Network, a leading online community for oncologists and others who treat cancer and the online home of the journal ONCOLOGY, presents exclusive coverage of the European Society for Medical Oncology (ESMO) 2014 Congress, held September 26–30 in Madrid, Spain.

8 Oct 2014

Combination treatment prevents disease progression in patients with advanced melanoma

New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.

30 Sep 2014

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).

30 Sep 2014

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.

10 Sep 2014

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.

1 Jul 2014

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

20 Jun 2014

Eventual drug resistance prevents long-term cure in most patients with metastatic melanoma

A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.

3 Jun 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

Virginia researchers develop new combination therapy that could potentially treat multiple myeloma

Each year, more than 25,000 Americans are diagnosed with multiple myeloma, a form of blood cancer that often develops resistance to therapies.

2 May 2014

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor Todd Bauer, MD, presented data at the 105th Annual Meeting of the American Association for Cancer Research (AACR), the premier cancer research event held in San Diego, California from April 5-9.

11 Apr 2014

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease.

8 Apr 2014

Study describes new tack in treatment of lung adenocarcinomas

The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients, researchers at Dana-Farber Cancer Institute and other scientists report in a new study.

31 Jan 2014

MEK Inhibitor News and Research

Researchers reveal how melanoma becomes resistant to promising new drug combo therapy

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

New research suggests potential role for MEK inhibitors in type 2 diabetes

Study reports anti-cancer activity in mice treated with experimental drug TAK-733

Researchers develop mouse model that reproduces most typical features of Noonan syndrome

Cancer Network presents exclusive coverage of ESMO 2014 Congress

Combination treatment prevents disease progression in patients with advanced melanoma

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Combination therapy achieves greater progression-free survival, response rates in melanoma

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

Eventual drug resistance prevents long-term cure in most patients with metastatic melanoma

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Virginia researchers develop new combination therapy that could potentially treat multiple myeloma

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Study describes new tack in treatment of lung adenocarcinomas

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest News